Abstract
More than 40,000 people have already been treated in Japan since September 2014 when the first interferon-free all-oral therapy with daclatasvir (DCV), an NS5A inhibitor, and asunaprevir (ASV), an NS3/4A protease inhibitor (PI), was approved for treatment of chronic hepatitis C virus genotype 1. On the other hand, regimens containing the nucleic acid-type NS5B polymerase inhibitor sofosbuvir in combination with a PI, NS5A inhibitor, and/or ribavirin are now becoming standard throughout the world and achieving greater than 95 % sustained virological response (SVR) rates against multiple HCV genotypes. On March 23, 2015, sofosbuvir was approved for treatment of genotype 2 in Japan, priced at 61,700 yen per pill. Furthermore, Harvoni, a combination drug containing sofosbuvir co-formulated with the NS5A inhibitor ledipasvir, was approved in Japan on July 3, 2015, for treatment of genotype 1 with pricing set at 81,171 yen per pill. While the 6,800,000 yen price tag of 12 weeks of Harvoni is higher than that of DCV/ASV therapy, the therapy is more effective, and the one pill per day dosing and 12-week duration provides simpler and shorter therapy. Similarly, sofosbuvir is approved for and effective against both genotypes 1 and 2. This review discusses the mechanism and characteristics of sofosbuvir and summarizes results of phase III clinical trials for genotypes 1 and 2 and reports on the effects of antiviral resistance.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- ASV:
-
Asunaprevir
- DAA:
-
Direct-acting antiviral
- DCV:
-
Daclatasvir
- HCV:
-
Hepatitis C virus
- LDV:
-
Ledipasvir
- PI:
-
Protease inhibitor
- RBV:
-
Ribavirin
- SOF:
-
Sofosbuvir
- SVR:
-
Sustained virological response
References
Omata M, Nishiguchi S, Ueno Y, Mochizuki H, Izumi N, Ikeda F, et al. Sofosbuvir plus ribavirin in Japanese patients with chronic genotype 2 HCV infection: an open-label, phase 3 trial. J Viral Hepat. 2014;21(11):762–8.
Mizokami M, Yokosuka O, Takehara T, Sakamoto N, Korenaga M, Mochizuki H, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis. 2015;15(6):645–53.
Kumada H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–9.
Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54(9):3641–50.
Wang C, Sun JH, O’Boyle 2nd DR, Nower P, Valera L, Roberts S, et al. Persistence of resistant variants in hepatitis C virus-infected patients treated with the NS5A replication complex inhibitor daclatasvir. Antimicrob Agents Chemother. 2013;57(5):2054–65.
Friborg J, Zhou N, Han Z, Yang X, Falk P, Mendez P, et al. In vitro assessment of re-treatment options for patients with hepatitis C virus genotype 1b infection resistant to daclatasvir plus asunaprevir. Infect Dis Ther. 2014.
Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368(1):34–44.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media Singapore
About this chapter
Cite this chapter
Hayes, C.N., Korenaga, M., Mizokami, M. (2017). Treatment Effects and Resistance-Associated Variants of Sofosbuvir Regimen for Japanese Patients with Chronic Hepatitis C Virus Genotypes 1 and 2. In: Chayama, K. (eds) Hepatitis C Virus Treatment. Springer, Singapore. https://doi.org/10.1007/978-981-10-2416-0_7
Download citation
DOI: https://doi.org/10.1007/978-981-10-2416-0_7
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-10-2415-3
Online ISBN: 978-981-10-2416-0
eBook Packages: MedicineMedicine (R0)